BridgeBio Pharma to Participate in the J.P. Morgan Healthcare Conference
BridgeBio Pharma (Nasdaq: BBIO), a biopharmaceutical company specializing in genetic diseases, has announced its participation in the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco. Co-founder and CEO Neil Kumar, Ph.D., will deliver a presentation on Monday, January 13 at 7:30 am PT.
Investors and interested parties can access the live webcast through the 'Events & Presentations' section of BridgeBio's investor website. The presentation recording will remain available for 30 days following the event on the company's website.
BridgeBio Pharma (Nasdaq: BBIO), un'azienda biofarmaceutica specializzata nelle malattie genetiche, ha annunciato la sua partecipazione al 43° Annual J.P. Morgan Healthcare Conference che si terrà a San Francisco. Il co-fondatore e CEO Neil Kumar, Ph.D., terrà una presentazione Lunedì 13 gennaio alle 7:30 ora del Pacifico.
Gli investitori e le persone interessate possono accedere alla diretta streaming attraverso la sezione 'Eventi e Presentazioni' del sito web per investitori di BridgeBio. La registrazione della presentazione rimarrà disponibile per 30 giorni dopo l'evento sul sito dell'azienda.
BridgeBio Pharma (Nasdaq: BBIO), una compañía biofarmacéutica especializada en enfermedades genéticas, ha anunciado su participación en la 43ª Conferencia Anual de Salud de J.P. Morgan en San Francisco. El cofundador y CEO Neil Kumar, Ph.D., realizará una presentación el lunes 13 de enero a las 7:30 am PT.
Los inversores y las partes interesadas pueden acceder a la transmisión en vivo a través de la sección 'Eventos y Presentaciones' del sitio web para inversionistas de BridgeBio. La grabación de la presentación estará disponible durante 30 días después del evento en el sitio web de la empresa.
브릿지바이오 제약 (Nasdaq: BBIO), 유전 질환을 전문으로 하는 생명공학 회사,가 샌프란시스코에서 열리는 제43회 JP 모건 헬스케어 컨퍼런스에 참여한다고 발표했습니다. 공동 창립자이자 CEO인 닐 쿠마르, Ph.D.가 1월 13일 월요일 오전 7시 30분 PT에 발표를 진행할 예정입니다.
투자자들과 관심 있는 분들은 브릿지바이오 투자자 웹사이트의 '이벤트 및 발표' 섹션을 통해 라이브 웹캐스트에 접근할 수 있습니다. 발표 녹화는 행사 이후 30일 동안 회사 웹사이트에서 이용 가능합니다.
BridgeBio Pharma (Nasdaq: BBIO), une entreprise biopharmaceutique spécialisée dans les maladies génétiques, a annoncé sa participation à la 43e Conférence Annuelle sur la Santé de J.P. Morgan à San Francisco. Le co-fondateur et PDG Neil Kumar, Ph.D., présentera un exposé le lundi 13 janvier à 7h30 PT.
Les investisseurs et les personnes intéressées peuvent accéder à la diffusion en direct via la section 'Événements et Présentations' du site Web pour les investisseurs de BridgeBio. L'enregistrement de la présentation restera disponible pendant 30 jours après l'événement sur le site de l'entreprise.
BridgeBio Pharma (Nasdaq: BBIO), ein biopharmazeutisches Unternehmen, das auf genetische Erkrankungen spezialisiert ist, hat seine Teilnahme an der 43. jährlichen J.P. Morgan Gesundheitskonferenz in San Francisco bekannt gegeben. Mitbegründer und CEO Neil Kumar, Ph.D., wird am Montag, den 13. Januar um 7:30 Uhr PT einen Vortrag halten.
Investoren und Interessierte können über den Bereich 'Veranstaltungen & Präsentationen' auf der Investorenseite von BridgeBio auf den Live-Stream zugreifen. Die Aufzeichnung der Präsentation wird 30 Tage nach der Veranstaltung auf der Website des Unternehmens verfügbar sein.
- None.
- None.
PALO ALTO, Calif., Jan. 08, 2025 (GLOBE NEWSWIRE) -- BridgeBio Pharma, Inc. (Nasdaq: BBIO) (“BridgeBio” or the “Company”), a new type of biopharmaceutical company focused on genetic diseases, today announced that co-founder and CEO, Neil Kumar, Ph.D., will present at the 43rd Annual J.P. Morgan Healthcare Conference in San Francisco, CA on Monday, January 13 at 7:30 am PT.
To access the live webcast of BridgeBio’s presentation, please visit the “Events & Presentations” page within the Investors section of the BridgeBio website at https://investor.bridgebio.com/news-and-events/event-calendar. A replay of the webcast will be available on the BridgeBio website for 30 days following the event.
About BridgeBio Pharma, Inc.
BridgeBio Pharma, Inc. (BridgeBio) is a new type of biopharmaceutical company founded to discover, create, test, and deliver transformative medicines to treat patients who suffer from genetic diseases. BridgeBio’s pipeline of development programs ranges from early science to advanced clinical trials. BridgeBio was founded in 2015 and its team of experienced drug discoverers, developers and innovators are committed to applying advances in genetic medicine to help patients as quickly as possible. For more information visit bridgebio.com and follow us on LinkedIn, Twitter and Facebook.
BridgeBio Media Contact:
Vikram Bali
contact@bridgebio.com
(650)-789-8220
FAQ
When is BridgeBio (BBIO) presenting at the 2025 J.P. Morgan Healthcare Conference?
How can investors watch BridgeBio's (BBIO) J.P. Morgan Healthcare Conference presentation?
How long will BridgeBio's (BBIO) J.P. Morgan Conference presentation replay be available?
Who is presenting for BridgeBio (BBIO) at the 2025 J.P. Morgan Healthcare Conference?
